SGLT1 Inhibitors
1 drugsAbout SGLT1
SGLT1 (sodium-glucose cotransporter 1) is a membrane protein that facilitates glucose and galactose absorption in the small intestine and kidney.
SGLT1 is an emerging drug target, particularly in cardiovascular disease, but currently lacks genetic evidence linking it to specific diseases.
INPEFA is the only FDA-approved drug targeting SGLT1, developed by LEXICON PHARMS INC for cardiovascular indications as a small molecule.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Obstructive Cardiomyopathy, Hypertrophic with only 1 trials.
Top Drugs
LEXICON PHARMS INC is the only company with an approved SGLT1-targeting drug.
The lack of competitors suggests a high barrier to entry or an unvalidated market, requiring careful risk assessment.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SGLT1, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing SGLT1-targeting therapies.
Clinical Trials 65 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 22 | 20 | 0 | 2 | 100% |
| Phase 2 | 14 | 5 | 2 | 7 | 71% |
| Phase 3 | 23 | 14 | 5 | 4 | 74% |
| Phase 4 | 6 | 3 | 1 | 2 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved SGLT1 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting SGLT1. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2023 - 2023)
The first and only SGLT1-targeting drug, INPEFA, was approved in 2023.
Recent approval suggests growing interest, but further approvals are needed to confirm sustained therapeutic value.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 56 clinical trials targeting SGLT1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities